Inhal has a comprehensive expertise in formulation development, and is capable of developing Carrier-free drug formulation and Carrier-based formulation.
Carrier-free formulation only contains micronized fine drug particles, which can be used in combination with matching inhaler devices to achieve excellent pulmonary drug delivery.
Carrier-based formulation uses large lactose (30-300 μm) as carriers to improve its flowability for easy handing, dispensing and metering of the drug. In most cases, the fine drug particles are attached onto the surface of the large lactose to form an ordered mixture that helps improve bulk property.
With expertise in dry powder formulation and devices, Inhal offers：
❖ A full range of service for particle size reduction, high-shear or low-shear mixing and formulation development;
❖ Overcome formulation challenges, such as low fine particle fraction and poor mixing uniformity;
❖ State-of-art characterization, including particle size distribution,in-vitrodrug deposition test, morphology, surface area test, delivered dose uniformity test, determination of crystallinity and crystallinity content, stability test, and dissolution test;
❖ Simulation of particle motion in inhaler device.
1. SBC 001 is one of the dry powder products developed by Ningbo Inhal Pharma with a reservoir-based device. Ningbo Inhal Pharma developed technologies to prepare “soft agglomerates” that improves the flowability of fine particles, making the handling of the cohesive pure drug particles easier.
2. LSS 002 is one of the dry powder products developed by Ningbo Inhal Pharma. LSS 002 uses the drug-lactose blends as formulation and achieves 32% of lung deposition rate if using the Inhal’s matched capsule-based inhaler device.